ZYNE Zynerba Pharmaceuticals Inc.

13.91
+0.47  (3%)
Previous Close 13.44
Open 13.43
Price To book 2.92
Market Cap 188534373
Shares 13,553,873
Volume 370,744
Short Ratio 4.69
Av. Daily Volume 848,410

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171198383
  2. 8-K - Current report 171198321
  3. 8-K - Current report 171131767
  4. 8-K - Current report 171105579
  5. 8-K - Current report 171079477

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 2018.
ZYN001
Fibromyalgia
Phase 2 to be initiated 2018.
ZYN001
Peripheral Neuropathic Pain (PNP)
Phase 2 data released September 28, 2017. Company noted data were positive with primary endpoint met. Note though that trial was uncontrolled/open-label. Phase 3 trial to commence 1H 2018.
ZYN002
Fragile X syndrome
Phase 2 data released August 14, 2017 - primary endpoint not met. However, company still intends to initiate Phase 3 trial pending discussions with FDA.
ZYN002 - STOP
Osteoarthritis
Phase 2 data released August 7, 2017 - endpoints not met.
ZYN002 - STAR 1
Adult Epilepsy Patients with Refractory Focal Seizures

Latest News

  1. Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES)
  2. Is It The Right Time To Buy Zynerba Pharmaceuticals Inc (ZYNE)?
  3. Zynerba reports 3Q loss
  4. Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights
  5. Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences
  6. 3 Marijuana Stocks That Like to Live Life Dangerously
  7. Like a Weed, This Marijuana Stock Catapulted Higher by 34% Last Week
  8. Zynerba's Recent Results Revitalize The Bull Case, But Risks Remain
  9. Zynerba Stock: Where Is It Headed From Here?
  10. Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
  11. Today's Research Reports on Stocks to Watch: Zynerba Pharmaceuticals and Loxo Oncology
  12. Zynerba Pharma (ZYNE) Stock Soars on Positive Cannabis-Based Drug Results
  13. Zynerba Pharma Wins Big on Cannabis Trial
  14. Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome
  15. This Marijuana Stock May Already Be Running Out of Chances to Succeed
  16. 5 Top Marijuana Stocks For 2017
  17. Of the 14 Largest Marijuana Stocks, Only These 2 Are Down Over the Past Year
  18. Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
  19. 2 Marijuana Stocks That Have Imploded Since August Began

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171198383
  2. 8-K - Current report 171198321
  3. 8-K - Current report 171131767
  4. 8-K - Current report 171105579
  5. 8-K - Current report 171079477
  6. 8-K - Current report 171026829
  7. 8-K - Current report 171009949
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 17996919
  9. 8-K - Current report 17994712
  10. 8-K - Current report 17987865